[Periotherapia Co., Ltd.] Periotherapia Co., Ltd. has been selected for the 2024 latest edition of Weekly Toyo Keizai’s “Amazing Venture 100”
*Periotherapy Co., Ltd.*
Press release: September 17, 2024
**
Periotherapy Co., Ltd. has been selected for the 2024 latest edition of Weekly Toyo Keizai’s “Amazing Venture 100”
*~We will develop new treatments for intractable diseases~*
Periotherapy Co., Ltd. (Headquarters: Suita City, Osaka Prefecture, Representative Director: Tochihara) is developing antibody drugs for intractable diseases.
Yosuke (hereinafter referred to as “Periotherapy”) is pleased to announce that he has been selected for the 2024 latest edition of Weekly Toyo Keizai’s startup special “Amazing Venture 100” in the “Drug Discovery” category.
* ◆What is “Amazing Venture 100”*
Weekly Toyo Keizai annually ranks venture companies aiming to become unicorns (unlisted companies that have been established for less than 10 years and have a valuation of $1 billion or more) based on criteria such as the amount of funding raised and the uniqueness of their business and technology. This is a unique feature that selects 100 promising venture companies from among them and analyzes each company’s business model and characteristics.
The September 21st and September 28th combined issue of Weekly Toyo Keizai, which was released on September 17th, featured the 2024 Latest Edition of the “Amazing Venture 100,” and our company was selected in the drug discovery category. Ta.
Toyo Keizai “100 Amazing Ventures” 2024 Latest Edition/Full List: https://toyokeizai.net/articles/-/824233
* ◆What is Periotherapy*
Our company is led by Yoshiaki Taniyama, a specially appointed professor in the Department of Advanced Molecular Therapeutics, Osaka University School of Medicine.
This is a drug discovery venture originating from Osaka University that was established by the director in October 2017. Periostin, an extracellular matrix protein involved in heart valve formation and wound healing, has pathological periostin variants (hereinafter referred to as “pathological periostin”) that are associated with various intractable diseases such as breast cancer, diabetic retinopathy, and myocardial infarction. We are working to clarify the factors involved in the development of drugs and target them.
In particular, we focused on the strong involvement of pathological periostin in triple-negative breast cancer (TNBC), which is difficult to treat among breast cancers, and selected metastatic and recurrent HER2-negative breast cancer, including TNBC, as the first indication for antibody drugs We are proceeding with the development of TNBC is more likely to affect young women (those in their 40s and raising children (AYA generation)), and is highly malignant with a 5-year survival rate of less than 50%, so there is hope for the early development of new therapeutic agents.
In addition to therapeutic drugs, we are also working on the development of companion diagnostic drugs, with the aim of increasing the success rate of clinical trials for the therapeutic drugs we develop and efficiently expanding our pipeline.
National Research and Development Agency
Selected as an implementing agency for the Japan Agency for Medical Research and Development (AMED)’s “Drug Discovery Venture Ecosystem Strengthening Project (Drug Discovery Venture Open Recruitment)” (3rd round) in 2025, and is conducting clinical trial development in Japan and the United States for the first indication. I have a goal of funding.
We aim to grow into a global specialty pharma company that represents Japan in the future.
* ■Company information*
Head office location: 2-8 Yamadaoka, Suita City, Osaka Prefecture Representative Director: Yosuke Tochihara
Main business: Development of antibody drugs
URL: https://periotherapia.co.jp/